Genetic gynecological tumor

Genetic gynecological tumors represent a broad category of tumors arising in the female reproductive tract (including the ovaries, uterus, fallopian tubes, vagina, and vulva) that have a hereditary or genetic basis. These tumors are distinguished from their sporadic counterparts by the presence of germline mutations in cancer predisposition genes. Well-known examples include hereditary ovarian cancer associated with BRCA1 and BRCA2 mutations (part of hereditary breast and ovarian cancer syndrome), endometrial cancer occurring in the context of Lynch syndrome (caused by mismatch repair gene mutations such as MLH1, MSH2, MSH6, and PMS2), and rare ovarian tumors such as small cell carcinoma of the ovary hypercalcemic type linked to SMARCA4 mutations. Other genetic conditions predisposing to gynecological tumors include Peutz-Jeghers syndrome (STK11 mutations, associated with sex cord tumors with annular tubules) and DICER1 syndrome (associated with Sertoli-Leydig cell tumors of the ovary). Clinical presentation varies widely depending on the specific tumor type and location. Symptoms may include abnormal uterine or vaginal bleeding, pelvic pain or pressure, abdominal distension, early satiety, and in some cases hormonal manifestations such as virilization or precocious puberty. Many hereditary gynecological tumors present at a younger age than their sporadic equivalents and may be bilateral (particularly ovarian tumors). A family history of gynecological, breast, or colorectal cancers is often a key diagnostic clue. Management depends on the specific tumor type and stage but generally includes surgical resection, often combined with chemotherapy or radiation therapy. Targeted therapies such as PARP inhibitors (e.g., olaparib, niraparib) have shown significant benefit in BRCA-associated ovarian cancers. Genetic counseling and testing are essential components of care, enabling risk-reducing strategies such as prophylactic salpingo-oophorectomy or enhanced surveillance for at-risk family members. Immunotherapy with checkpoint inhibitors may be considered for mismatch repair-deficient endometrial cancers.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic gynecological tumor